NYSE:QGEN - New York Stock Exchange, Inc. - NL0015002CX3 - Common Stock - Currency: USD
42.32
0 (0%)
The current stock price of QGEN is 42.32 USD. In the past month the price decreased by -1.72%. In the past year, price decreased by -3.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 18.29 | 151.18B | ||
DHR | DANAHER CORP | 25.17 | 134.17B | ||
A | AGILENT TECHNOLOGIES INC | 20.66 | 31.27B | ||
IQV | IQVIA HOLDINGS INC | 12.22 | 24.34B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 28.08 | 23.67B | ||
WAT | WATERS CORP | 29.26 | 20.73B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.4 | 14.98B | ||
ILMN | ILLUMINA INC | 24.19 | 12.75B | ||
RVTY | REVVITY INC | 18.35 | 10.87B | ||
ICLR | ICON PLC | 9.26 | 10.48B | ||
TEM | TEMPUS AI INC | N/A | 10.25B | ||
AVTR | AVANTOR INC | 12.73 | 8.76B |
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,765 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
QIAGEN N.V.
Hulsterweg 82
Venlo LIMBURG 5912 NL
CEO: Thierry Bernard
Employees: 5232
Phone: 31773556600
The current stock price of QGEN is 42.32 USD.
The exchange symbol of QIAGEN N.V. is QGEN and it is listed on the New York Stock Exchange, Inc. exchange.
QGEN stock is listed on the New York Stock Exchange, Inc. exchange.
25 analysts have analysed QGEN and the average price target is 50.15 USD. This implies a price increase of 18.49% is expected in the next year compared to the current price of 42.32. Check the QIAGEN N.V. stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QIAGEN N.V. (QGEN) has a market capitalization of 9.15B USD. This makes QGEN a Mid Cap stock.
QIAGEN N.V. (QGEN) currently has 5232 employees.
QIAGEN N.V. (QGEN) has a support level at 42.31 and a resistance level at 42.41. Check the full technical report for a detailed analysis of QGEN support and resistance levels.
The Revenue of QIAGEN N.V. (QGEN) is expected to grow by 4.01% in the next year. Check the estimates tab for more information on the QGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QIAGEN N.V. (QGEN) has a dividend yield of 0.59%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of QGEN dividend history, reliability and sustainability.
QIAGEN N.V. (QGEN) will report earnings on 2025-07-31, after the market close.
The PE ratio for QIAGEN N.V. (QGEN) is 18.4. This is based on the reported non-GAAP earnings per share of 2.3 and the current share price of 42.32 USD. Check the full fundamental report for a full analysis of the valuation metrics for QGEN.
The outstanding short interest for QIAGEN N.V. (QGEN) is 2.38% of its float. Check the ownership tab for more information on the QGEN short interest.
ChartMill assigns a technical rating of 5 / 10 to QGEN. When comparing the yearly performance of all stocks, QGEN turns out to be only a medium performer in the overall market: it outperformed 62.36% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to QGEN. QGEN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months QGEN reported a non-GAAP Earnings per Share(EPS) of 2.3. The EPS increased by 11.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 4.23% | ||
ROA | 1.47% | ||
ROE | 2.34% | ||
Debt/Equity | 0.38 |
ChartMill assigns a Buy % Consensus number of 76% to QGEN. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 8.07% and a revenue growth 4.01% for QGEN